US/UK/Canada

Share

Contacts

  • Bent U. Frandsen

    CEO


    +45 2222 1019
    http://www.expres2ionbio.com
  • Keith Alexander

    CFO


    +45 2222 1019
    http://www.expres2ionbio.com
    • Pick a time period -
    Tags ( Active)

    Publication of clinical Phase IIb trial data for the adjuvanted RH5.1 blood-stage malaria vaccine

    Hørsholm, Denmark, 11 December 2024 – ExpreS2ion Biotech Holding AB’s affiliate ExpreS2ion Biotechnologies ApS (“ExpreS2ion") announces the new publication in The Lancet Infectious Diseases titled “Safety and efficacy of the blood-stage malaria vaccine RH5.1/Matrix-M in Burkina Faso: interim results of a double-blind, randomised, controlled phase 2b trial in children”. The article is based on a clinical study conducted by researchers at the University of Oxford. The promising results reported by the University of Oxford further validate the potential of these vaccine candidates in the fight

    Analysguiden Publishes Research Report on ExpreS2ion Biotech with Price Target of SEK 91

    Hørsholm, Denmark, 11 December 2024 – ExpreS2ion Biotech Holding AB’s affiliate ExpreS2ion Biotechnologies ApS (“ExpreS2ion") is pleased to announce that Analysguiden has published a detailed research report analysing the company’s recent progress and setting a price target of SEK 91.The report provides an independent assessment of ExpreS2ion’s development pipeline and strategic initiatives, focusing on the approval to initiate a Phase I clinical trial for the company’s HER2-targeted therapeutic breast cancer vaccine, ES2B-C001. Key highlights from the report include: · Progress in

    Warrants of series TO 10 were exercised to approximately 69 percent and ExpreS2ion receives approximately SEK 10 million

    NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, WITHIN OR TO THE UNITED STATES, AUSTRALIA, BELARUS, CANADA, HONG KONG, JAPAN, NEW ZEALAND, SOUTH AFRICA, RUSSIA, SOUTH KOREA, SWITZERLAND OR IN ANY OTHER JURISDICTION WHERE SUCH RELEASE, DISTRIBUTION OR PUBLICATION WOULD BE UNLAWFUL OR WOULD REQUIRE REGISTRATION OR ANY OTHER MEASURES. Hørsholm, Denmark, 6 December 2024 - Today ExpreS2ion Biotech Holding AB ("ExpreS2ion" or the "Company") announces the outcome of the exercise of warrants of series TO 10, which were issued in connection with the Company'

    ExpreS2ion announces approval to initiate a Phase I clinical trial of ES2B-C001, its novel therapeutic vaccine, being developed for HER2-expressing breast cancer

    Hørsholm, Denmark, 2 December 2024 – ExpreS2ion Biotech Holding AB’s affiliate ExpreS2ion Biotechnologies ApS (“ExpreS2ion"), a clinical-stage biotechnology company with a focused portfolio of vaccine candidates targeting infectious diseases and cancer, is proud to announce the approval of its Phase I clinical trial application (CTA) by the Austrian Agency for Health and Food Safety for its novel therapeutic vaccine candidate, ES2B-C001, against HER2-expressing breast cancer.Bent U. Frandsen, Chief Executive Officer said: “This is the first time we advance a development project into the

    ExpreS2ion publishes video presentations from Biostock Life Science Summit and Analysguiden Stora Aktiedagarna

    Hørsholm, Denmark, 2 December 2024 – ExpreS2ion Biotech Holding AB’s subsidiary ExpreS2ion Biotechnologies ApS (“ExpreS2ion") announces that filmed company presentations in which CEO Bent Frandsen shared insights into the company’s development strategy and value creation potential are now available on the company’s website.The first presentation was delivered at the Biostock Life Science Summit on 21 November 2024. The second took place at the Aktiespararna event Stora Aktiedagarna in Stockholm on 27 November 2024. Both presentations highlighted ExpreS2ion’s novel HER2-targeted therapeutic

    Last day of trading in warrants of series TO 10 in Expres2ion Biotech Holding AB is today, 2 December 2024

    NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, WITHIN OR TO THE UNITED STATES, AUSTRALIA, BELARUS, CANADA, HONG KONG, JAPAN, NEW ZEALAND, SOUTH AFRICA, RUSSIA, SOUTH KOREA, SWITZERLAND OR IN ANY OTHER JURISDICTION WHERE SUCH RELEASE, DISTRIBUTION OR PUBLICATION WOULD BE UNLAWFUL OR WOULD REQUIRE REGISTRATION OR ANY OTHER MEASURES. Hørsholm, Denmark, 2 December 2024 - ExpreS2ion Biotech Holding AB ("ExpreS2ion" or the "Company") announces that today is the last day of trading in warrants of series TO 10. The exercise period for the warrants of

    ExpreS2ion Biotechnologies: Full commitments from members of ExpreS2ion's Board and Management holding warrants of series TO 10

    NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, WITHIN OR TO THE UNITED STATES, AUSTRALIA, BELARUS, CANADA, HONG KONG, JAPAN, NEW ZEALAND, SOUTH AFRICA, RUSSIA, SOUTH KOREA, SWITZERLAND OR IN ANY OTHER JURISDICTION WHERE SUCH RELEASE, DISTRIBUTION OR PUBLICATION WOULD BE UNLAWFUL OR WOULD REQUIRE REGISTRATION OR ANY OTHER MEASURES. Hørsholm, Denmark, 21 November 2024 - ExpreS2ion Biotech Holding AB's ("ExpreS2ion" or the "Company") announces that all members of the Company’s Board and Management holding warrants of series TO 10, including the

    ExpreS2ion Biotechnologies: ExpreS2ion announces the start of the exercise period for warrants of series TO 10

    NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, WITHIN OR TO THE UNITED STATES, AUSTRALIA, BELARUS, CANADA, HONG KONG, JAPAN, NEW ZEALAND, SOUTH AFRICA, RUSSIA, SOUTH KOREA, SWITZERLAND OR IN ANY OTHER JURISDICTION WHERE SUCH RELEASE, DISTRIBUTION OR PUBLICATION WOULD BE UNLAWFUL OR WOULD REQUIRE REGISTRATION OR ANY OTHER MEASURES. Hørsholm, Denmark, 20 November 2024 - ExpreS2ion Biotech Holding AB ("ExpreS2ion" or the "Company") announces that today begins the exercise period for the warrants of series TO 10, which were issued in connection with

    ExpreS2ion to present in upcoming investor and scientific events

    Hørsholm, Denmark, 18 November 2024 – ExpreS2ion Biotech Holding AB’s subsidiary ExpreS2ion Biotechnologies ApS (“ExpreS2ion") will participate in upcoming investor and scientific events, including the BioStock Life Science Summit, the Immunotherapies and Innovations for Infectious Diseases Congress and Aktiespararna’s Stora Aktiedagen.By attending relevant industry and investor events, the company aims to increase the awareness of its technology platform and its exciting development pipeline. More information on each event and how to register is found below and on the Company’s website (

    ExpreS2ion announces TO 10 warrant exercise price and start of exercise period

    NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, WITHIN OR TO THE UNITED STATES, AUSTRALIA, BELARUS, CANADA, HONG KONG, JAPAN, NEW ZEALAND, SOUTH AFRICA, RUSSIA, SOUTH KOREA, SWITZERLAND OR IN ANY OTHER JURISDICTION WHERE SUCH RELEASE, DISTRIBUTION OR PUBLICATION WOULD BE UNLAWFUL OR WOULD REQUIRE REGISTRATION OR ANY OTHER MEASURES. Hørsholm, Denmark, 14 November 2024 - ExpreS2ion Biotech Holding AB ("ExpreS2ion" or the "Company") announces that the exercise price for the warrants of series TO 10 has been determined to SEK 17.91 and that the

    Correction: ExpreS2ion announces financial results for the third quarter of 2024

    Hørsholm, Denmark, 14 November 2024 – ExpreS2ion Biotech Holding AB (“ExpreS2ion”) today announces its third quarter and year-to-date financial results for 2024. The report is available as an attachment and on ExpreS2ion's website (www.expres2ionbio.com). Below is a summary of the report. This press release is a correction to the press release made earlier this morning, which did not include the report as an attachment.CEO Bent U. Frandsen comments: “We achieved substantial milestones in the third quarter of 2024, notably submitting the clinical trial application for our breast cancer

    ExpreS2ion announces financial results for the third quarter of 2024

    Hørsholm, Denmark, 14 November 2024 – ExpreS2ion Biotech Holding AB (“ExpreS2ion”) today announces its third quarter and year-to-date financial results for 2024. The report is available as an attachment and on ExpreS2ion's website (www.expres2ionbio.com). Below is a summary of the report.CEO Bent U. Frandsen comments: “We achieved substantial milestones in the third quarter of 2024, notably submitting the clinical trial application for our breast cancer vaccine candidate, ES2B-C001. This marks our most significant milestone for this proprietary asset. We also advanced key partnerships,

    ExpreS2ion and Evaxion announce positive preclinical data for cytomegalovirus (CMV) vaccine program ES2B-I002

    Hørsholm, Denmark, 12 November 2024 – ExpreS2ion Biotech Holding AB’s affiliate ExpreS2ion Biotechnologies ApS (“ExpreS2ion"), a clinical-stage biotechnology company with a focused pipeline of vaccine candidates targeting infectious diseases and cancer, today announced that positive new preclinical data from its ongoing cytomegalovirus (CMV) vaccine program collaboration with Evaxion Biotech A/S (“Evaxion”), named ES2B-I002, will be presented at the 9[th] International Conference on Vaccines Research & Development, in Boston, USA.The data indicate that the antigens identified through

    ExpreS2ion CEO talking to BioStock about partnering efforts at BIO-Europe

    Heading towards phase I studies with breast cancer vaccine candidate ES2B-C001, ExpreS2ion Biotech is actively looking for partners. Also, having a well-validated platform, the company recently announced signing a term sheet with Serum Institute of India regarding a malaria vaccine. BioStock talked to CEO Bent U. Frandsen about this at the partnering conference BIO-Europe.See the full interview at biostock.se : https://www.biostock.se/2024/11/expres2ion-ceo-talking-about-partnering-efforts-at-bio-europe/ This is a press release from BioStock - Connecting

    ExpreS2ion Biotech will present at the BioStock Life Science Summit, November 21

    The seventh edition of the BioStock Life Science Summit will take place in Lund on November 20-21. CEO Bent U. Frandsen will present ExpreS2ion Biotech to industry leaders, specialist investors and potential partners.The Summit connects innovation and capital, providing small-to-medium size Nordic companies from a wide range of therapeutic areas the platform and opportunity to make their case to both Swedish and international investors as well as top-level potential partners in a unique boutique setting.    Date: 21 November Time: 10:50  Location: Auditorium at Medicon Village,

    ExpreS2ion to present in upcoming investor and scientific events

    Hørsholm, Denmark, 31 October2024 – ExpreS2ion Biotech Holding AB’s subsidiary ExpreS2ion Biotechnologies ApS (“ExpreS2ion") will participate in upcoming investor and scientific events, including BIO-Europe, the Protein & Antibody Engineering Summit Europe, a 2024 Third Quarter Results Webinar, and the LSX Investival Showcase.By attending relevant industry and investor events, the company aims to increase the awareness of its technology platform and its exciting development pipeline. More information on each event and how to register is found below and on the Company’s website 

    The Board of Directors of ExpreS2ion Biotech Holding AB (publ) has resolved on the record date for the reverse share split

    Hørsholm, Denmark, 24 October 2024 - At the Extraordinary General Meeting of ExpreS2ion Biotech Holding AB (publ) ("ExpreS2ion" or the "Company") on 21 October 2024, it was resolved on a reverse share split of the Company's shares, whereby forty (40) existing shares shall be consolidated into one (1) share (Sw. sammanläggning 1:40). The Board of Directors was authorized by the Extraordinary General Meeting to determine the record date for the reverse share split. The Board of Directors has today resolved that the record date for the reverse share split shall be 31 October 2024. Due to the

    Bulletin from the Extraordinary General Meeting of ExpreS2ion Biotech Holding AB (publ)

    Today, on 21 October 2024, ExpreS2ion Biotech Holding AB ("ExpreS2ion" or the "Company") has held an Extraordinary General Meeting 2024 (the "EGM"). Notice of the EGM and complete proposals for resolutions taken are available on the Company's investor website, https://investor.expres2ionbio.com.Resolution on a directed issue of shares (equalization issue)The EGM resolved, in accordance with the Board of Directors' proposal, on an issue of not more than 384,530 new shares with deviation from the shareholders' preferential rights. Through the share issue, the Company's share capital will

    ExpreS2ion and Serum Institute of India have entered in a term sheet regarding proposed development and commercialisation of novel malaria vaccines

    Hørsholm, Denmark, 16 October 2024 – ExpreS2ion Biotech Holding AB’s affiliate ExpreS2ion Biotechnologies ApS (“ExpreS2ion"), a clinical-stage biotechnology company with a focused pipeline of vaccine candidates targeting infectious diseases and cancer, announces that a term sheet has been entered with Serum Institute of India Private Limited (“SIIPL”), the world’s largest vaccine manufacturer. Upon execution of a definitive agreement on terms to be mutually agreed, SIIPL will obtain exclusive licensing rights to develop, manufacture, and commercialise certain malaria vaccine product lines,

    Notice to attend the Extraordinary General Meeting in ExpreS2ion Biotech Holding AB (publ)

    N.B. This notice has been prepared in both Swedish and English language versions. In the event of any discrepancies between the versions, the Swedish version shall prevail. The shareholders of ExpreS2ion Biotech Holding AB (publ), reg. no. 559033-3729 (the "Company"), are hereby given notice to attend the Extraordinary General Meeting to be held on 21 October 2024 at 10.00 (CEST) on Mindpark, Bredgatan 11, Helsingborg, Sweden. The entrance to the meeting and registration will commence at 09.30 (CEST).The Board of Directors have decided, pursuant to the Company’s articles of association,

    ExpreS2ion to present in upcoming investor events

    Hørsholm, Denmark, 10 September 2024 – ExpreS2ion Biotech Holding AB’s affiliate ExpreS2ion Biotechnologies ApS (“ExpreS2ion") will participate in upcoming investor events, including Investing in Life Science: From Seed to Success and a Danish Stock seminar for institutional investors.By attending relevant industry and investor events, the company aims to increase the awareness of its technology platform and its exciting development pipeline. More information on each event and how to register is found below and on the Company’s website and via the links below. 12 September 2024 |

    ExpreS2ion announces publication of sponsored research reports

    Hørsholm, Denmark, 23 August 2024 – ExpreS2ion Biotech Holding AB (Nasdaq First North Growth Market: EXPRS2) is pleased to announce the publication of two new research reports by sponsored analysts, which delve into the fundamentals of the company’s innovative pipeline and proprietary ExpreS2 platform.The reports, authored by Analysguiden and Pareto Securities, provide detailed analyses of ExpreS2ion’s lead asset, ES2B-C001, and the broader development pipeline. Key Highlights: · Analysguiden Report: Titled “At the Gates of Phase I,” this report emphasizes the outlook for ES2B-C001

    ExpreS2ion announces financial results for the second quarter of 2024

    Hørsholm, Denmark, 15 August 2024 – ExpreS2ion Biotech Holding AB (“ExpreS2ion”) today announces its second quarter and half-year financial results for 2024. The report is available as an attachment and on ExpreS2ion's website (www.expres2ionbio.com). Below is a summary of the report.CEO Bent U. Frandsen comments:“On the first of July, we announced the completion of a rights issue raising gross proceeds of SEK 30 million. With a cash position of SEK 68.6 million at the end of the second quarter, ExpreS2ion is funded to initiate the ES2B-C001 first-in-human Phase I trial, subject to

    There are no items matching the current filter
    There are no more items matching the current filter
    Back to top

    Subscribe

    Media